AI Analysis
AI-generated analysis. Always verify with the original filing.
Forte Biosciences deepened its operating and net losses in 2025 amid sustained clinical investments in its pre-revenue development stage, with cash burn accelerating due to higher operating expenses while EPS improved from prior-year levels on increased share count.
Key Takeaways
1Operating loss widened 93% to -$70.7M from -$36.6M as the Company continued research and development activities including drug manufacturing and clinical trial costs.
2Net loss increased 96% to -$69.4M from -$35.5M, reflecting the trajectory of operating losses incurred in each year since inception with no products approved for commercial sale.
3Diluted EPS improved 61% to -$4.71 from -$12.17, driven by doubled share count from prior financings that supported higher average cash balances.
4Net cash used in operating activities rose to -$50.9M from -$30.7M, primarily consisting of net losses adjusted for non-cash items in this pre-revenue biotech.
5Interest income increased from higher average cash and cash equivalents balances, while other expense, net rose primarily due to foreign exchange losses.